Clinical trial
A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of…
NCT00355524 · Tibotec Pharmaceuticals, Ireland, Industry · Completed
Key facts
| NCT number | NCT00355524 |
|---|---|
| Title | A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents |
| Official title | A Phase II, Open-label Trial, to Investigate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of TMC114/Rtv b.i.d in Treatment-Experienced HIV-1 Infected Children and Adolescents |
| Lead sponsor | Tibotec Pharmaceuticals, Ireland, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV-1, HIV Infections |
| Intervention type | Drug |
| Interventions | TMC114, Ritonavir |
| Enrollment | 80 |
| Start date | Jun 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Mar 1, 2011 |
| First posted | Jul 24, 2006 |
| Last update posted | Jul 8, 2013 |
| Countries | Argentina, Brazil, Canada, France, Romania, South Africa, Spain, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: